Luqa Pharma In-Licenses Scar Treatment from Stratapharma
Luqa Pharmaceuticals, a Hong Kong company that specializes in dermatology products, has in-licensed exclusive China rights to Strataderm®, a scar treatment, from Stratpharma AG of Switzerland. Strataderm has already been approved by the SFDA; Luqa plans to begin marketing the drug to hospital and retail accounts in Q4 of 2012. More details.... Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here